HSVICP0 recruits USP7 to modulate TLR-mediated innate response

Blood

Volumn 113, Issue 14, 2009, Pages 3264-3275

  Daubeuf, Sandrine ^a   Singh, Divyendu ^b   Tan, Yaohong ^b   Liu, Hongiu ^b   Federoff, Howard J ^c   Bowers, William J ^d   Tolba, Khaled ^b  

^a CNRS   (France)

^b UNIVERSITY OF MIAMI   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE GAMMA; ICP0 PROTEIN; IMMEDIATE EARLY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN SPECIFIC PROTEASE 7; UNCLASSIFIED DRUG; I KAPPA B KINASE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN; VMW110 PROTEIN, HUMAN HERPESVIRUS 1;

ADAPTIVE IMMUNITY; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; EMBRYO; ENZYME ACTIVATION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; NEGATIVE FEEDBACK; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT; UBIQUITINATION; VIRUS PATHOGENESIS; CELL CULTURE; GENETICS; HERPES SIMPLEX; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN PROCESSING;

CELLS, CULTURED; HERPES SIMPLEX; HUMANS; I-KAPPA B KINASE; IMMEDIATE-EARLY PROTEINS; IMMUNITY, INNATE; NF-KAPPA B; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTORS; UBIQUITIN; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASES;

EID: 65349175161     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-168203     Document Type: Article

References (64)

1. Mossman KL, Ashkar AA. Herpesviruses and the innate immune response. Viral Immunol. 2005; 18:267-281.
2. Hochrein H, Schlatter B, O'Keeffe M, et al. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc Natl Acad Sci U S A. 2004;101:11416-11421.
3. Malmgaard L, Melchjorsen J, Bowie AG, Mogensen SC, Paludan SR. Viral activation of macrophages through TLR-dependent and -independent pathways. J Immunol. 2004;173:6890-6898.
4. Aravalli RN, Hu S, Rowen TN, Palmquist JM, Lokensgard JR. Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol. 2005;175:4189-4193.
5. Kurt-Jones EA, Chan M, Zhou S, et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A. 2004;101:1315-1320.
6. Zhang SY, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 2007;317:1522-1527.
7. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med. 2003;198:513-520.
8. Cheng G, Zhong J, Chung J, Chisari FV. Double- stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. Proc Natl Acad Sci USA. 2007;104:9035-9040.
9. Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature. 2007;448: 501-505.
10. Lundberg P, Welander P, Han X, Cantin E. Herpes simplex virus type 1 DNA is immunos- timulatory in vitro and in vivo. J Virol. 2003;77: 11158-11169.
11. Ishii KJ, Coban C, Kato H, et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol. 2006;7:40-48.
12. Jacquemont B, Roizman B. RNA synthesis in cells infected with herpes simplexvirus, X: Properties of viral symmetric transcripts and of double- stranded RNA prepared from them. J Virol. 1975; 15:707-713.
13. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. Double-stranded RNAis produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNAviruses. J Virol. 2006;80:5059-5064.
14. Murphy JA, Duerst RJ, Smith TJ, Morrison LA. Herpes simplex virus type 2 virion host shutoff protein regulates alpha/beta interferon but not adaptive immune responses during primary infection in vivo. J Virol. 2003;77:9337-9345.
15. Poppers J, Mulvey M, Khoo D, Mohr I. Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J Virol. 2000;74:11215-11221.
16. He B, Chou J, Brandimarti R, Mohr I, Gluzman Y Roizman B. Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol. 1997; 71:6049-6054.
17. Fruh K, Ahn K, Djaballah H, et al. Aviral inhibitor of peptide transporters for antigen presentation. Nature. 1995;375:415-418.
18. Hill A, Jugovic P, York I, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature. 1995;375:411-415.
19. Eidson KM, Hobbs WE, Manning BJ, Carlson P, DeLuca NA. Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimu- lated genes by viral infection. J Virol. 2002;76: 2180-2191.
20. Melroe GT, DeLuca NA, Knipe DM. Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production. J Virol. 2004; 78:8411-8420.
21. Tolba KA, Bowers WJ, Hilchey SP, et al. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood. 2001;98:287-295.
22. Everett RD, Meredith M, Orr A. The ability of herpes simplex virus type 1 immediate-early protein Vmw110 to bind to a ubiquitin-specific protease contributes to its roles in the activation of gene expression and stimulation of virus replication.J Virol. 1999;73:417-426.
23. Canning M, Boutell C, Parkinson J, Everett RD. A RING finger ubiquitin ligase is protected from au- tocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7. J Biol Chem. 2004;279:38160-38168.
24. Lomonte P, Everett RD. Herpes simplex virus type 1 immediate-early protein Vmw110 inhibits progression of cells through mitosis and from G(1) into S phase of the cell cycle. J Virol. 1999; 73:9456-9467.
25. Federoff H. Growth of Replication Defective Herpes Virus Amplicon Vectors and Their Use for Gene Transfer. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1997.
26. Bowers WJ, Howard DF, Brooks AI, Halterman MW, Federoff HJ. Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers. Gene Ther. 2001;8:111-120.
27. Bowers WJ, Howard DF, Federoff HJ. Discordance between expression and genome transfer titering of HSV amplicon vectors: recommendation for standardized enumeration [In Process Citation]. Mol Ther. 2000;1:294-299.
28. Li Y, Jiang Z, Chen H, Ma WJ. Amodified quantitative EMSA and its application in the study of RNA: protein interactions. J Biochem Biophys Methods. 2004;60:85-96.
29. Samaniego LA, Wu N, DeLuca NA. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol. 1997;71:4614-4625.
30. Wu N, Watkins SC, Schaffer PA, DeLuca NA. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J Virol. 1996;70:6358-6369.
31. Tolba K, Bowers W, Eling D, et al. HSV amplicon- mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. Mol Ther. 2002;6:455.
32. Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13:816-825.
33. Melroe GT, Silva L, Schaffer PA, Knipe DM. Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: potential role in blocking IFN-beta induction. Virology. 2007;360:305-321.
34. Mullen MA, Ciufo DM, Hayward GS. Mapping of intracellular localization domains and evidence for colocalization interactions between the IE110 and IE175 nuclear transactivator proteins of herpes simplex virus. J Virol. 1994;68:3250-3266.
35. Lin R, Noyce RS, Collins SE, Everett RD, Mossman KL. The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-me- diated activation of interferon-stimulated genes. J Virol. 2004;78:1675-1684.
36. Everett RD, Meredith M, Orr A, Cross A, Kathoria M, Parkinson J. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 1997;16:566-577.
37. Boutell C, Canning M, Orr A, Everett RD. Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7. J Virol. 2005;79:12342-12354.
38. Zapata JM, Pawlowski K, Haas E, Ware CF, Godzik A, Reed JC. Adiverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem. 2001;276: 24242-24252.
39. Hu M, Li P, Li M, et al. Crystal structure of a UBP- family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 2002;111: 1041-1054.
40. Holowaty MN, Sheng Y, Nguyen T, Arrowsmith C, Frappier L. Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP. J Biol Chem. 2003;278:47753-47761.
41. Sheng Y, Saridakis V, Sarkari F, et al. Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol. 2006;13:285-291.
42. Saridakis V, Sheng Y, Sarkari F, et al. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell. 2005; 18:25-36.
43. Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19:24-32.
44. Wertz IE, O'Rourke KM, Zhou H, et al. De-ubiq- uitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004;430:694-699.
45. Salio M, Cella M, Suter M, LanzavecchiaA. Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol. 1999;29:3245-3253.
46. Nicholl MJ, Robinson LH, Preston CM. Activation of cellular interferon-responsive genes after infection of human cells with herpes simplex virus type 1. J Gen Virol. 2000;81:2215-2218.
47. Mossman KL, Macgregor PF, Rozmus JJ, GoryachevAB, Edwards AM, Smiley JR. Herpes simplex virus triggers and then disarms a host antiviral response. J Virol. 2001;75:750-758.
48. Mossman KL, Saffran HA, Smiley JR. Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol. 2000;74:2052-2056.
49. Amici C, Rossi A, Costanzo A, et al. Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J Biol Chem. 2006;281:7110-7117.
50. Gregory D, Hargett D, Holmes D, Money E, Bachenheimer SL. Efficient replication by herpes simplex virus type 1 involves activation of the IkappaB kinase-IkappaB-p65 pathway. J Virol. 2004;78:13582-13590.
51. Santoro MG, Rossi A, Amici C. NF-kappaB and virus infection: who controls whom. EMBO J. 2003;22:2552-2560.
52. Medici MA, Sciortino MT, Perri D, et al. Protection by herpes simplex virus glycoprotein D against Fas-mediated apoptosis: role of nuclear factor kappaB. J Biol Chem. 2003;278:36059-36067.
53. Yamamoto M, Okamoto T, Takeda K, et al. Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat Immunol. 2006;7:962-970.
54. FukushimaT, Matsuzawa S, Kress CL, et al. Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc Natl Acad Sci USA. 2007;104:6371-6376.
55. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem. 2007; 282:4102-4112.
56. Ni CY, Wu ZH, Florence WC, et al. Cutting edge: K63-linked polyubiquitination of NEMO modu-lates TLR signaling and inflammation in vivo. J Immunol. 2008;180:7107-7111.
57. Mukhopadhyay D, Riezman H. Proteasome-inde- pendent functions of ubiquitin in endocytosis and signaling. Science. 2007;315:201-205.
58. Lindner HA. Deubiquitination in virus infection. Virology. 2007;362:245-256.
59. Rytkönen A, Holden DW. Bacterial interference of ubiquitination and deubiquitination. Cell Host Microbe. 2007;1:13-22.
60. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 2005;7:758-765.
61. Lim JH, Stirling B, Derry J, et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity. 2007;27:349-360.
62. Boone DL, Turer EE, Lee EG, et al. The ubiquitin- modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004;5:1052-1060.
63. Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC. Coordinated regulation of Toll-like receptor and NOD2 signaling by K63- linked polyubiquitin chains. Mol Cell Biol. 2007; 27:6012-6025.
64. Saito K, Kigawa T, Koshiba S, et al. The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKgamma. Structure. 2004; 12:1719-1728.